


Quality Measures Desktop Reference for Medicaid Providers

HEDIS[®] is a widely used set of performance measures developed and maintained by NCQA. These are used to drive improvement efforts surrounding best practices.



Please note: The information provided is based on HEDIS MY2024 technical specifications and is subject to change based on guidance given by the National Committee for Quality Assurance (NCQA), CMS, and state recommendations. Please refer to the appropriate agency for additional guidance. HEDIS[®] is a registered trademark of the National Committee for Quality Assurance (NCQA).

Patient care opportunities

You can find patient care opportunities within the Patient360 application located on Availity Essentials **Payer Spaces**. To access the *Patient360* application, you must have the *Patient360* role assignment. From the Availity home page, select **Payer Spaces**, then choose the health plan from the menu. Choose the **Patient360** tile from the **Payer Space** *Applications* menu and complete the required information on the screen. Gaps in care are located in the **Active Alerts** section of the *Member Summary*.



Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)	 Members with a diagnosis of pregnancy Members who use hospice services or elect to use a hospice benefit any time during the measurement year Members who die any time during the measurement year 	Ages 3 to 17	Annual	 The percentage of members who had an outpatient visit with a PCP or OB/GYN during the measurement year in which the following were documented: BMI Percentile Documentation* Counseling for Nutrition Counseling for Physical Activity * Because BMI norms for youth vary with age and gender, this measure evaluates whether BMI percentile is assessed rather than an absolute BMI value.
Immunizations for Adolescents (IMA)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year Members who die any time during the measurement year 	Ages 13	Multiple doses	The percentage of members who had 1 dose of meningococcal vaccine, 1 tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccine, and have completed the human papillomavirus (HPV) vaccine series by their 13th birthday. The measure calculates a rate for each vaccine and two combination rates:
				 Meningococcal vaccine between 11th and 13th birthday
				 Tdap vaccine between 10th and 13th birthday
				HPV vaccine between 9th and 13th birthday
Lead Screening in Children (LSC)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. Members who die any time during the measurement year 	Ages 0 to 2	Once before age 2	The percentage of members who had one or more capillary or venous lead blood test by their 2nd birthday

Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Cervical Cancer Screening (CCS)	 Members who use hospice services or elect to use a hospice benefit any time 	Age 21 to 64	Varies by age	The percentage of members who were recommended for routine cervical cancer screening and were screened for cervical cancer using any of the following criteria:
	during the measurement yearMembers who die any time during the measurement year			 Members 21 to 64 years of age who were recommended for routine cervical cancer screening and had cervical cytology performed within the last 3 years
	Hysterectomy with no residual cervix			 Members 30 to 64 years of age who were recommended for routine cervical cancer screening and had cervical high-risk human papillomavirus (hrHPV) testing performed
	 Cervical agenesis or acquired absence of cervix 			within the last 5 years
	 Members receiving palliative care 			 Members 30 to 64 years of age who were recommended for routine cervical cancer screening and had cervical cytology/high-risk human papillomavirus (hrHPV)
	 Members who had an encounter for palliative care 			cotesting within the last 5 years
	 Members with Sex Assigned at Birth of Male anytime in the patient's history 			
Childhood Immunization Status (CIS)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year 	Ages 0 to 2	Multiple doses	The percentage of members who had appropriate doses of the following vaccines on or before their 2nd birthday:
				 4 diphtheria, tetanus, and acellular pertussis (DTaP)
	 Members who die any time 			• 3 polio (IPV)
	 during the measurement year Members who had a contraindication to a childhood vaccine on or before their second birthday 			 1 measles, mumps, and rubella (MMR) (can only be given on or between first and second birthday to close the gap)
				 3 haemophilus influenza type B (HiB)
				 3 hepatitis B (One of the three vaccinations can be a newborn hepatitis B vaccination during the eight-day period that begins on the date of birth and ends seven days after the date of birth)
	2			 1 chicken pox (VZV) (can only be given on or between first and second birthday to close the gap)
				 4 pneumococcal conjugate (PCV)
27				 1 hepatitis A (HepA) (can only be given on or between first and second birthday to close the gap)
110				 2 two-dose RV or 3 three-dose rotavirus (RV) (Or 1 two-dose and two three-dose RV combination)
			11	 2 influenza (flu) (Influenza cannot be given until infant is 6 months of age — 1 of the two vaccinations for influenza can be an LAIV administered on the child's second birthday).

Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Chlamydia Screening in Women (CHL)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year 	Ages 16 to 24	Annual	Percentage of members who were identified as sexually active and who had at least one screening test for chlamydia during the measurement year
	 Members who die any time during the measurement year 			
Oral Evaluation, Dental Services (OED)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year 	Ages 0 to 20	Annual	The percentage of members under 21 years of age who received a comprehensive or periodic oral evaluation with a dental provider during the measurement year
	 Members who die any time during the measurement year 			
Topical Fluoride for Children (TFC)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year 	Ages 1 to 4	Annual	The percentage of members who received at least two fluoride varnish applications during the measurement year
	 Members who die any time during the measurement year 			
Appropriate Testing for Pharyngitis (CWP)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year 	Ages 3 years and older	Each occurence	The percentage of episodes for members who have been diagnosed with pharyngitis, dispensed an antibiotic, and received group A streptococcus (strep) test for the episode
	 Members who die any time during the measurement year 			
Pharmacotherapy Management of COPD Exacerbation (PCE)	• Members who use hospice services or elect to use a hospice benefit any time during the measurement year	Ages 40 and older	Inpatient discharge or ED event	The percentage of COPD exacerbations for members who had an acute inpatient discharge or emergency department (ED) visit on or between January 1 to November 30 of the measurement year and who were dispensed appropriate medications. Two rates are reported:
	 Members who die any time during the measurement year 			 Dispensed a systemic corticosteroid (or there was



- **Dispensed a systemic corticosteroid** (or there was evidence of an active prescription) within 14 days of the event
- **Dispensed a bronchodilator** (or there was evidence of an active prescription) within 30 days of the event

Note: The eligible population for this measure is based on acute inpatient discharges and ED visits, not on members. It is possible for the denominator to include multiple events for the same individual.

Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Asthma Medication Ratio (AMR)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year 	Ages 5 to 64	Annual	The percentage of members who have been identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year
	 Members who die any time during the measurement year 			
	• Members who had a diagnosis that requires a different treatment approach than members with asthma any time during the member's history through December 31 of the measurement year.			
	 Members who had no asthma controller or reliever medications during the measurement year 			



Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year Members who die any time during the measurement year 	Ages 18 and older	After discharge	The percentage of members who were hospitalized and discharged from July 1 of the year prior to the measurement year to June 30 of the measurement year with a diagnosis of AMI (Acute myocardial infarction) and who received persistent beta-blocker treatment for 180 days (6 months) after discharge
	 Members with a medication dispensing event that indicates a contraindication to beta-blocker therapy 	-		
	• Members with a diagnosis that indicates a contraindication to beta-blocker therapy any time during the member's history through the end of the continuous enrollment period meet criteria		-	
	• Members 66 to 80 years of age as of December 31 of the measurement year with frailty and advanced illness. Members must meet both frailty and advanced illness criteria to be excluded.			
	• Members 81 years of age and older as of December 31 of the measurement year (all product lines) with at least two indications of frailty with different dates of service during the measurement year			

Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Controlling High Blood Pressure (CBP)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year 	Ages 18 to 85	Annual	The percentage of members who had a diagnosis of hypertension (HTN) and whose blood pressure (BP) was adequately controlled (< 140/90 mm Hg) during the measurement year.
	 Members who die any time during the measurement year 			The final BP of the measurement year is captured.
	 Members receiving palliative care any time during the measurement year 			Note: The most recent BP reading during the measurement year on or after the second diagnosis of hypertension. If multiple BP measurements occur on the same date or are
	 Members who had an encounter for palliative care anytime during the measurement year. 			noted in the chart on the same date, use the lowest systolic and lowest diastolic BP reading. If no BP is recorded during the measurement year, assume that the member is <i>not controlled</i> .
	• Members with a diagnosis that indicates end-stage renal disease (ESRD) any time during the member's history on or prior to December 31 of the measurement year	n di	1	
	• Members with a procedure that indicates ESRD: dialysis any time during the member's history on or prior to December 31 of the measurement year			
	 Members with a diagnosis of pregnancy any time during the measurement year 			
	 Members 66 to 80 years of age as of December 31 of the measurement year (all product lines) with frailty and advanced illness. Members must meet both frailty and advanced illness criteria to be excluded Members 81 years of age and older as of December 31 of the measurement year (all product lines) with at least two indications of frailty with different dates of service during the measurement year 			

Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Statin Therapy for Patients with Cardiovascular Disease (SPC)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year 	Men ages 21 to 75 Women ages 40 to 75	Annual	The percentage of members who are identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria. The following rates are reported: • Received Statin Therapy: Members who were dispensed
	 Members who die any time during the measurement year 			at least one high- or moderate-intensity statin medication during the measurement year
	 Members with a diagnosis of pregnancy during the measurement year or the year prior to the measurement year 			• Statin Adherence 80%: Members who remained on a high- or moderate-intensity statin medication for at least 80% of the treatment period (treatment period begins with the earliest dispensing event for any high-intensity
	 In vitro fertilization in the measurement year or the year prior to the measurement year 			or moderate-intensity statin medication during the measurement year).
	 Dispensed at least one prescription for clomiphene during the measurement year or the year prior to the measurement year 			
	 End stage renal disease (ESRD) during the measurement year or the year prior to the measurement year 			
	 Dialysis during the measurement year or the year prior to the measurement year 			
	 Cirrhosis during the measurement year or the year prior to the measurement year 			
	 Myalgia, myositis, myopathy, or rhabdomyolysis during the measurement year 			
	 Members receiving palliative care any time during the measurement year 			the state of the s
	 Members who had an encounter for palliative anytime during the measurement year 		1 JA	me

Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Statin Therapy for Patients with Cardiovascular Disease (SPC) (cont.)		Men ages 21 to 75 Women ages	Annual	The percentage of members who are identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria. The following rates were reported:
	year (all product lines) with frailty and advanced illness. Members must meet both frailty and advanced illness	40 to 75		 Received Statin Therapy: Members who were dispensed at least one high- or moderate-intensity statin medication during the measurement year
	criteria to be excluded.			• Statin Adherence 80%: Members who remained on a high- or moderate-intensity statin medication for at least 80% of the treatment period (treatment period begins with the earliest dispensing event for any high-intensity or moderate-intensity statin medication during the measurement year).
Cardiac Rehabilitation (CRE)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year 	Ages 18 and older	Annual	• The percentage of members who have attended cardiac rehabilitation following a qualified cardiac event including, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, heart and heart/lung transplantation or heart valve repair/replacement.
	 Members who die any time during the measurement year 			 Four rates are reported:
	 Members receiving palliative care any time during the measurement year. 			 Initiation: the percentage of members who attended 2 or more sessions of cardiac rehabilitation within 30 days after a qualifying event
	 Members who had an encounter for palliative anytime during the measurement year. 			 Engagement 1: the percentage of members who attended 12 or more sessions of cardiac rehabilitation within 90 days after a qualifying event
	 Members 66–80 years of age as of December 31 of the measurement year (all product) 			 Engagement 2: the percentage of members who attended 24 or more sessions of cardiac rehabilitation within 180 days after a qualifying event
	lines) with frailty and advanced illness. Members must meet both frailty and advanced illness criteria to be excluded.			 Achievement: the percentage of members who attended 36 or more sessions of cardiac rehabilitation within 180 days after a qualifying event.
	• Members 81 years of age and older as of December31ofthemeasurement year (all product lines) with at least two indications of frailty with different dates of service during the measurement year.			

Measure	Exclusions	Eligible population	Occurence	 Description of measurement screening, test, or treatment needed
Cardiac Rehabilitation (CRE) (cont,)	 Discharged from an inpatient setting with any of the following on the discharge claim during the 180 days after the episode date: Myocardial Infarction (MI) 	Ages 18 and older	Annual	• The percentage of members who have attended cardiac rehabilitation following a qualified cardiac event including, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, heart and heart/lung transplantation or heart valve repair/replacement on or between July 1 of the year prior to the measurement year to June 30 of the measurement year.
	 Coronary artery bypass areft (CARC) 			Four rates are reported:
	graft (CABG) – Heart or heart/lung transplant			 Initiation: the percentage of members who attended 2 or more sessions of cardiac rehabilitation within 30 days after a qualifying event
	Heart valve repair or replacementPercutaneous Coronary			 Engagement 1: the percentage of members who attended 12 or more sessions of cardiac rehabilitation within 90 days after a qualifying event
	Intervention (PCI)			 Engagement 2: the percentage of members who attended 24 or more sessions of cardiac rehabilitation within 180 days after a qualifying event
				 Achievement: the percentage of members who attended 36 or more sessions of cardiac rehabilitation within 180 days after a qualifying event.
Glycemic Status Assessment for Patients with Diabetes (GSD)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year 	Ages 18 to 75	Annual	• The percentage of members with diabetes (types 1 and 2) whose most recent glycemic status (hemoglobin A1c [HbA1c] or glucose management indicator [GMI]) was at the following levels during the measurement year:
	Members who die any time			• Glycemic Status (< 8%)
	during the measurement year			 Glycemic Status (> 9%)
	 Members receiving palliative care any time during the measurement year. 			Note: Organizations must use the same data collection method (administrative or hybrid) to report these indicators.
	 Members who had an encounter for palliative anytime during the measurement year. 			
	 Members 66 years of age and older as of December 31 of the measurement year (all product lines) with frailty and advanced illness. Members must meet both frailty and advanced illness criteria to be excluded. 			

Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Blood Pressure Control Patients with Diabetes (BPD)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year 	Ages 18 to 75	Annual	The percentage of members with diabetes (types 1 and 2) whose blood pressure (BP) was adequately controlled (< 140/90 mm Hg) during the measurement year
	 Members who die any time during the measurement year 			The final BP of the measurement year is captured.
	 Members receiving palliative care any time during the measurement year. 			
	 Members who had an encounter for palliative anytime during the measurement year. 			
	 Members 66 years of age and older as of December 31 of the measurement year (all product lines) with frailty and advanced illness. Members must meet both frailty and advanced illness criteria to be excluded. 			



Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Eye Exam for Patients with Diabetes (EED)	services or elect to use a	Ages 18 to 75	Annual	The percentage of members with diabetes (types 1 and 2) who had one of the following:
	hospice benefit any time during the measurement year			 A retinal or dilated eye exam by an eye care professional (optometrist or ophthalmologist) in the measurement year
	 Members who die any time during the measurement year 			 A negative retinal or dilated eye exam (negative for retinopathy) by an eye care professional in the year prior
	Members receiving palliative are any time during the			to the measurement year
	care any time during the measurement year	9		 Bilateral eye enucleation any time during the member's history through December 31 of the measurement year
	 Members who had an encounter for palliative anytime during the measurement year 			
	 Members 66 years of age and older as of December 31 of the measurement year (all product lines) with frailty and advanced illness. Members must meet both frailty and advanced illness criteria to be excluded. 			



Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Kidney Health Evaluation for Patients with Diabetes (KED)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year Members who die any time during the measurement year 	Ages 18 to 85	Annual	The percentage of members with diabetes (type 1 and type 2) who received a kidney health evaluation, defined by an estimated glomerular filtration rate (eGFR) and a urine albumin-creatinine rate (uACR), during the measurement year.
	 Members receiving palliative care any time during the measurement year 		-	
	 Members who had an encounter for palliative care anytime during the measurement year. 			
	 Members with a diagnosis of end-stage renal disease (ESRD) any time during the member's history on or prior to December 31 of the measurement year. 			
	 Members who had dialysis any time during the member's history on or prior to December 31 of the measurement year 		-	
	 Members 66 to 80 years of age as of December 31 of the measurement year (all product lines) with frailty and advanced illness. Members must meet both frailty and advanced illness criteria to be excluded. 			
	• Members 81 years of age and older as of December 31 of the measurement year (all product lines) with at least two indications of frailty with different dates of service during the measurement year.			
	Advanced illness on at least two different dates of service.		and a state of the	
	 Dispensed dementia medication 		1 Ale	

Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Measure Statin Therapy for Patients with Diabetes (SPD)	 Members with at least one of the following during the year prior to the measurement year in any setting: Myocardial Infarction (MI) Coronary artery bypass graft (CABG) Percutaneous Coronary Intervention (PCI) Other revascularization procedure Members who had at least one encounter with a diagnosis of IVD during both the measurement year and the year prior to the measurement year or year prior to the measurement year or year prior to the measurement year In vitro fertilization in the measurement year or year prior to the measurement year Dispensed at least one prescription for clomiphene during the measurement year End stage renal disease (ESRD) during the measurement year or the year prior to the measurement year Dialysis during the 	Eligible population Ages 40 to 75	Occurence Annual	
	 Dialysis during the measurement year or the year prior to the measurement year Cirrhosis during the measurement year or the year prior to the measurement year Myalgia, myositis, myopathy, or rhabdomyolysis during the 			
	measurement year	le and the	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	the stars and the second

Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Statin Therapy for Patients with Diabetes (SPD) (cont.)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year Members who die any time during the measurement year Members receiving palliative care any time during the measurement year Members who had an encounter for palliative care any time during the measurement year Members 66 years of age and older as of December 31 of the measurement year (all product lines) with frailty and advanced illness. Members must meet both frailty and advanced illness criteria to be excluded. 	Ages 40 to 75	Annual	<text><list-item><list-item></list-item></list-item></text>
Diagnosed Mental Health Disorders (DMH)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year Members who die any time during the measurement year 	1 year or older	Annual	The percentage of members who were diagnosed with a mental health disorder during the measurement yearNote: The measure provides information on the diagnosed prevalence of mental health disorders. Neither a higher nor lower rate indicates better performance.
Antidepressant Medication Management (AMM)		Ages 18 and older	Per episode	 The percentage of members who were treated with antidepressant medication, had a diagnosis of major depression and who remained on an antidepressant medication treatment May 1 of the year prior to the measurement year to April 30 of the measurement year. Two rates are reported: Effective acute phase treatment: the percentage of members who remained on an antidepressant medication for at least 84 days (12 weeks) Effective continuation phase treatment: the percentage of members who remained on an antidepressant medication for at least 180 days (6 months)

Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Follow-Up After Hospitalization for Mental Illness (FUH)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. Members who die any time 	Ages 6 and older	Within seven and/or 30 days after discharge	The percentage of discharges for members who were hospitalized for treatment of selected mental illness or intentional self-harm diagnoses and who had a follow-up visit with a mental health provider during the measurement year. Two rates are reported:
	during the measurement year.			 The percentage of discharges for which the member received follow-up within 30 days after discharge
				 The percentage of discharges for which the member received follow-up within 7 days after discharge
Follow-Up After Emergency Department Visit for Mental Illness (FUM)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. Members who die any time 	0	Within seven and/or 30 days after ED visit	The percentage of emergency department (ED) visits with a principal diagnosis of mental illness or intentional self-harm, who had a follow-up visit for mental illness with any practitioner type during the measurement year. Two rates are reported:
	during the measurement year.			 The percentage of ED visits for which the member received follow-up within 30 days of the ED visit (31 total days)
				 The percentage of ED visits for which the member received follow-up within 7 days of the ED visit (8 total days)
Diagnosed Substance Use Disorders (DSU)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. Members who die any time 	Ages 13 years or older	Annual	The percentage of members who were diagnosed with a substance use disorder during the measurement year. Four rates are reported:
				 The percentage of members diagnosed with an alcohol disorder
	during the measurement year.			 The percentage of members diagnosed with an opioid disorder
		12		 The percentage of members diagnosed with a disorder for other or unspecified drugs
				 The percentage of members diagnosed with any substance use disorder
		2	5	Note: The measure provides information on the diagnosed prevalence of substance use disorders. Neither a higher nor lower rate indicates better performance.

any time surement year.	Ages 13 years and older	Within seven and/or 30 days after discharge	Percentage of acute inpatient hospitalizations, residential treatment, or withdrawal management visits for a diagnosis of substance use that result in a follow-up visit or service for substance use disorder during the measurement year. Two rates are reported:
surement year.			 The percentage of visits or discharges for which the member received follow-up for substance use disorder within the 30 days after the visit or discharge
			 The percentage of visits or discharges for which the member received follow-up for substance use disorder within the 7 days after discharge
			Note: Follow-up visits on the same day of the visit or discharge do not meet this measure.
	Ages 13 years and older	Within seven and/or 30 days after	The percentage of emergency department (ED) visits among members with a principal diagnosis of substance use disorder (SUD), or any diagnosis of drug overdose, for which there was follow-up during the measurement year. Two rates
	ED visit	 are reported: The percentage of ED visits for which the member received follow-up within 30 days of the ED visit (31 total days) 	
			 The percentage of ED visits for which the member received follow-up within seven days of the ED visit (eight total days)
			Note: Follow-up visits that occur on the same day as the ED discharge meet this measure.
t to use a any time surement year. lie any time	Ages 16 years and older	Annual	The percentage of opioid use disorder (OUD) pharmacotherapy events that lasted at least 180 days with a diagnosis of OUD and a new OUD pharmacotherapy event
	surement year. lie any time surement year. lies hospice t to use a any time surement year. lie any time surement year.	surement year. lie any time surement year. lise hospice t to use a any time surement year. lie any time surement year. lise hospice t to use a any time surement year. lie any time surement year. lie any time surement year. lie any time surement year. lie any time surement year.	surement year.days after dischargelie any time surement year.Ages 13 years and olderWithin seven and/or 30 days after ED visitlie any time surement year.Ages 16 years and olderMithin seven and/or 30 days after ED visitlie any time surement year.Ages 16 years and olderAnnual older

Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed	
Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. 	Ages 18 to 64	Annual	The percentage of members with schizophrenia, schizoaffective disorder, or bipolar disorder, who were dispensed an antipsychotic medication and had a diabetes screening test (glucose test and/or HbA1c test) during the	
Medications (SSD)	 Members who die any time during the measurement year. 			measurement year	
	 Members with diabetes 				
	 Members who had no antipsychotic medications dispensed during the measurement year. 				
Diabetes Monitoring for People with Diabetes and Schizophrenia (SMD)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. 	Ages 18 to 64	Annual	Percentage of members with schizophrenia or schizoaffective disorder and diabetes who had both an LDL-C and an HbA1c test during the measurement year	
	 Members who die any time during the measurement year. 				
Cardiovascular Monitoring for People with Cardiovascular Disease and Schizophrenia (SMC)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. 	Ages 18 to 64	Annual		Percentage of members with schizophrenia, schizoaffective disorder and cardiovascular disease who had an LDL-C test during the measurement year
	 Members who die any time 			Note: Indicators of cardiovascular disease include:	
	during the measurement year.			 Inpatient discharge for acute myocardial infarction (AMI) or coronary artery bypass grafting (CABG) during the 	



 Diagnosis of percutaneous coronary intervention (PCI) in any setting during the year

year

 Diagnosis of ischemic vascular disease (IVD) during an inpatient or outpatient visit in both the current year and the prior year

Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. 	Ages 18 years and older	Annual	The percentage of members with schizophrenia or schizoaffective disorder who were dispensed and remained on the antipsychotic medication for at least 80% of their treatment period
	 Members who die any time during the measurement year. 			
	 Members who had a diagnosis of dementia 			
	 Members who <i>did not</i> have at least two antipsychotic medication dispensing events. 			
	 Members 66 to 80 years of age as of December 31 of the measurement year (all product lines) with frailty and advanced illness. Members must meet both frailty and advanced illness criteria to be excluded. 			
	 Members 81 years of age and older as of December 31 of the measurement year (all product lines) with at least two indications of frailty with different dates of service during the measurement year 			

Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Multiple Providers (UOP) services or elect to use a hospice benefit any time	Ages 18 years and older	Annual	The percentage of members receiving prescription opioids for \geq 15 days during the measurement year who received opioids from multiple providers. Three rates are reported:	
	during the measurement year.Members who die any time during the measurement year.			 Multiple prescribers: the percentage of members receiving prescriptions for opioids from four or more different prescribers during the measurement year
				 Multiple pharmacies: the percentage of members receiving prescriptions for opioids from four or more different pharmacies during the measurement year
				• Multiple prescribers and multiple pharmacies: the percentage of members receiving prescriptions for opioids from four or more different prescribers and four or more different pharmacies during the measurement year (for example, the percentage of members who are numerator compliant for both the multiple prescribers and multiple pharmacies rates).
				Note: A lower rate indicates better performance for all three rates.
Risk of Continued Opioid Use (COU)	 Members who use hospice services or elect to use a hospice benefit any time 	Ages 18 years and older	Annual	The percentage of members who have a new episode of opioid use that puts them at risk for continued opioid use. Two rates are reported:
	 during the measurement year. Members who die any time during the measurement year. 			 The percentage of members with at least 15 days of prescription opioids in a 30-day period
	Members who met at least one			 The percentage of members with at least 31 days of prescription opioids in a 62-day period
	of the following at any time during the 365 days prior to the IPSD through 61 days after the IPSD:			Note: Lower rate indicates higher performance.
	the IPSD: – Cancer – Sickle cell disease			
	 Members receiving palliative care any time during the measurement year. 			
	 Members who had an encounter for palliative care any time during the measurement year. 			

Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Appropriate Treatment for Upper Respiratory Infection (URI)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. 	Ages 3 months and older	Per occurence	The percentage of episodes for members with a diagnosis of upper respiratory infection (URI) that did not result in an antibiotic dispensing event
	 Members who die any time during the measurement year. 			
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. 	Ages 3 months and older	Per occurrence	The percentage of episodes for members with a diagnosis of acute bronchitis/bronchiolitis that did not result in an antibiotic dispensing event
	 Members who die any time during the measurement year. 			



	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Use of Imaging Studies for Low Back Pain (LBP)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year 	Ages 18 to 75	Not applicable	Percentage of members who had a primary diagnosis of lower back pain and did not have an imaging study (for example, plain X-ray, MRI, or CT scan) within 28 days of the diagnosis
	 Members who die any time during the measurement year 			
	 Members 66 years of age and older as of December 31 of the measurement year (all product lines) with frailty and advanced illness. Members must meet both frailty and advanced illness criteria to be excluded. 		6	
	 Members meet any of the following criteria: 			
	- Cancer			
	 Recent trauma 		-	
	 Intravenous drug abuse 			
	 Neurological impairment 			
	– HIV			
	 Spinal infection 			
	 Major organ transplant 		Carlos .	
	 Prolonged use of corticosteroids 	The second second		
	– Osteoporosis		6	
	 Lumbar surgery 			
	 Spondylopathy 			
	 Fragility fracture 			
	 Spondylopathy 			

Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Use of Opioids at High Dosage (HDO)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. 	Ages 18 years and older	Annual	The percentage of members who received prescription opioids at a high dosage (average morphine milligram equivalent dose [MME] \ge 90) for \ge 15 days during the measurement year.
	 Members who die any time during the measurement year. 			Note: Lower rate indicates higher performance.
	 Member who meet the following criteria: 			
	– Cancer			
	– Sickle Cell			
	 Members receiving palliative care any time during the measurement year. 			
	 Members who had an encounter for palliative care any time during the measurement year. 			
Adults' Access to Preventive/Ambulatory Health Services (AAP)	 Members who use hospice services or elect to use a hospice benefit any time 	Ages 20 and older Annua	Annual	The percentage of members who had an ambulatory or preventive care visit. The organization reports three separate percentages for each product line.
	during the measurement year.Members who die any time			 Medicaid and Medicare members who had an ambulatory or preventive care visit during the measurement year.
	during the measurement year.			 Commercial members who had an ambulatory or preventive care visit during the measurement year or the 2 years prior to the measurement year.
Initiation and Engagement of Substance Use Disorder Treatment (IET)	hospice benefit any time	Ages 13 and older	Per episode	The percentage of new substance use disorder (SUD) episodes that result in treatment initiation and engagement. Two rates are reported:
()	during the measurement year.Members who die any time during the measurement year.			• Initiation of SUD treatment: the percentage of new SUD episodes that result in treatment initiation through an inpatient SUD admission, outpatient visit, intensive outpatient encounter, partial hospitalization, telehealth visit, or medication treatment within 14 days
				 Engagement of SUD treatment: the percentage of new SUD episodes that have evidence of treatment engagement within 34 days of initiation

Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Prenatal and Postpartum Care (PPC)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. Members who die any time 	Live birth	Per occurrence	The percentage of deliveries of live births on or between October 8 of the year prior to the measurement year and October 7 of the measurement year. For these members, the measure assesses the following facets of prenatal and postpartum care:
	during the measurement year.			• Timeliness of prenatal care: the percentage of deliveries that received a prenatal care visit in the first trimester, on or before the enrollment start date or within 42 days of enrollment in the organization
				 Postpartum care: the percentage of deliveries that had a postpartum visit on or between 7 and 84 days after delivery
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. 	Ages 1 to 17	Annual	The percentage of members who had a new prescription for an antipsychotic medication and had documentation of psychosocial care as first-line treatment
	 Members who die any time during the measurement year. Members for whom first-line antipsychotic medications may be clinically appropriate: members with a diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, other psychotic disorder, autism or other developmental disorder on at least two different dates of service during the measurement year. 			
Well-Child Visits in the First 30 Months of Life (W30)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. Members who die any time during the measurement year. 	Ages 0 to 15 months Ages 15 to 30 months	Six visits Two visits	 Members who had the following number of well-child visits with a PCP during the last 15 months. The following rates are reported: Well-child visits in the first 15 months: children who turned 15 months old during the measurement year: six or more well-child visits Well-child visits for age 15 to 30 months: children who turned 30 months old during the measurement year: two or more well-child visits

Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Child and Adolescent Well-Care Visits (WCV)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. 	Ages 3 to 21	Annual	Members who had at least one comprehensive well-care visit with a PCP or an OB/GYN practitioner during the measurement year
	 Members who die any time during the measurement year. 			
Antibiotic Utilization for Respiratory Conditions (AXR)	Members who use hospice services or elect to use a hospice benefit any time during the measurement year.	Ages 3 months and older	Per episode	The percentage of episodes for members with a diagnosis of a respiratory condition that resulted in an antibiotic dispensing event
Plan All-Cause Readmissions (PCR)	Members who use hospice services or elect to use a hospice benefit any time during the measurement year.	Ages 18 to 64 years	Per occurrence	The number of acute inpatient and observation stays during the measurement year that were followed by an unplanned acute readmission for any diagnosis within 30 days and the predicted probability of an acute readmission.
Childhood Immunization Status (CIS-E)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. 	Ages 0 to 2	Multiple doses	The percentage of members who had appropriate doses of the following vaccines on or before their 2nd birthday:
				 4 diphtheria, tetanus, and acellular pertussis (DTaP)
	 Members who die any time 			• 3 polio (IPV)
	Members who had a			 1 measles, mumps, and rubella (MMR) (can only be give on or between first and second birthday to close the gap
	contraindication to a childhood			 3 haemophilus influenza type B (HiB)
	vaccine on or before their second birthday.			 3 hepatitis B (hepB) (One of the three vaccinations can be a newborn hepatitis B vaccination during the eight-d period that begins on the date of birth and ends seven days after the date of birth.)
				 1 chicken pox (VZV) (can only be given on or between first and second birthday to close the gap)
		ALL A		4 pneumococcal conjugate (PCV)
		*****		 1 hepatitis A (HepA) (can only be given on or between first and second birthday to close the gap)
N/1		++++++		 2 two-dose rotavirus (RV) or 3 three-dose rotavirus (RV) (Or one two-dose and two three-dose RV combination)
		NTXX I		• 2 influenza (flu) (influenza cannot be given until infant

 2 influenza (flu) (influenza cannot be given until infant is 6 months of age — One of the two vaccinations for influenza can be an LAIV administered on the child's second birthday).

Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Immunizations for Adolescents (IMA-E)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. Members who die any time during the measurement year. 	Ages 13	Multiple doses	 The percentage of members who had one dose of meningococcal vaccine, one tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccine, and have completed the human papillomavirus (HPV) vaccine series by their 13th birthday. Meningococcal vaccine between 11th and 13th birthday Tdap vaccine between 10th and 13th birthday HPV vaccine between 9th and 13th birthday
Breast Cancer Screening (BCS-E)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. Members who die any time during the measurement year. Members who had a bilateral mastectomy or both right and left unilateral mastectomies any time during the member's history through the end of the measurement period. Members who had gender-affirming chest surgery with a diagnosis of gender dysphoria any time during the member's history through the end of the measurement period. Members 66 years of age and older as of December 31 of the measurement year (all product lines) with frailty and advanced illness. Members must meet both frailty and advanced illness criteria to be excluded. Members who die any time during the measurement year Members who die any time during the measurement year. Members who die any time during the measurement year. 	Ages 50 to 74	Annual	<text></text>

Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed	
Cervical Cancer Screening (CCS-E)	 Members who use hospice services or elect to use a hospice benefit any time 	Ages 21 to 64	age	The percentage of members who were recommended for routine cervical cancer screening and were screened for cervical cancer using any of the following criteria:	
	during the measurement year.Members who die any time during the measurement year.			• Members 21 to 64 years of age who were recommended for routine cervical cancer screening and had cervical cytology performed within the last 3 years.	
	 Hysterectomy with no residual cervix any time during the member's history through December 31 of the 	e d d		for routine cervical cancer screening	 Members 30 to 64 years of age who were recommended for routine cervical cancer screening and had cervical high-risk human papillomavirus (hrHPV) testing performed within the last 5 years.
	 measurement year Cervical agenesis or acquired absence of cervix any time during the member's history through the end of the measurement period. 			 Members 30 to 64 years of age who were recommended for routine cervical cancer screening and had cervical cytology/high-risk human papillomavirus (hrHPV) contesting within the last 5 years 	
	 Members receiving palliative care any time during the measurement period. 				
	 Members who had an encounter for palliative care any time during the measurement period. 				
	 Members with Sex Assigned at Birth at any time during the patient's history. 				



Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Colorectal Cancer Screening (COL-E)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. Members who die any time during the measurement year. Members 66 years of age and older as of December 31 of the measurement year (all product lines) with frailty and advanced illness. Members must meet both frailty and advanced illness criteria to be excluded. Members receiving palliative care any time during the measurement year. Members who had an encounter for palliative care any time during the measurement year. Members who had colorectal cancer any time during the member's history through December 31 of the measurement year. Members who had a total colectomy any time during the member's history through December 31 of the measurement year. 	Ages 45 to 75	Dependent on screening type	<text><list-item><list-item><list-item></list-item></list-item></list-item></text>

Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Follow-Up Care for Children Prescribed ADHD Medication (ADD-E)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. Members who die any time during the measurement year. 	Ages 6 to 12	Varies by phase	The percentage of children newly prescribed attention-deficit/hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 10-month period, one of which was within 30 days of when the first ADHD medication was dispensed during the measurement year. Two rates are reported:
	 Members with a diagnosis of narcolepsy any time during the member's history through the end of the measurement period. 			• Initiation phase: the percentage of members 6 to 12 years of age with a prescription dispensed for ADHD medication, who had one follow-up visit with a practitioner with prescribing authority during the 30-day initiation phase
				• Continuation and maintenance (C&M) phase: the percentage of members 6 to 12 years of age with a prescription dispensed for ADHD medication, who remained on the medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two follow-up visits with a practitioner within 270 days (nine months) after the initiation phase ended.
Metabolic Monitoring for Children and Adolescents on Antipsychotics	 Members who use hospice services or elect to use a hospice benefit any time 	Ages 1 to 17	Annual	Members who had two or more antipsychotic prescriptions and had metabolic testing during the measurement year. Three rates are reported:
(APM-E)	during the measurement year.Members who die any time			 The percentage of children and adolescents on antipsychotics who received blood glucose testing
	during the measurement year.			 The percentage of children and adolescents on antipsychotics who received cholesterol testing
				 The percentage of children and adolescents on antipsychotics who received both blood glucose and cholesterol testing.
Depression Screening and Follow-up for Adolescents and Adults (DSF-E)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. Members who die any time during the measurement year. Members with a history of bipolar any time during the member's history through the end of the year prior to the measurement period. 	Ages 12 and older	Per episode	The percentage of members who were screened for clinical depression using a standardized instrument and, if screened positive, received follow-up care:
				 Depression screening: The percentage of members who were screened for clinical depression using a standardized instrument.
				 Follow-up on positive screen: The percentage of members who received follow-up care within 30 days of a positive depression screen finding.
	• Members with depression that starts during the year prior to the measurement period.			

Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Unhealthy Alcohol Use Screening and Follow-Up (ASF-E)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. 	Ages 18 years and older	Per episode	The percentage of members who were screened for unhealthy alcohol use using a standardized instrument and, if screened positive, received appropriate follow-up care during the measurement year.
	 Members who die any time during the measurement year. 		 Unhealthy Alcohol Use Screening: The percentage of members who had a systematic screening for unhealthy alcohol use 	
	 Members with alcohol use disorder that starts during the year prior to the measurement period. 		 Follow-Up Care on Positive Screen: The percentage of members receiving brief counseling or other follow-up care within 60 days (2 months) of screening positive for 	
	 Members with history of dementia any time during the member's history through the end of the measurement period. 			unhealthy alcohol use
Depression Remission or Response for Adolescents and Adults (DRR-E)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. 	Ages 12 and older	Per episode	The percentage of members with a diagnosis of depression and an elevated PHQ-9 score, who had evidence of response or remission within 120-240 days (4-8 months) of the elevated score:
	 Members who die any time during the measurement year. 			Follow-Up PHQ-9: The percentage of members who have a follow-up PHQ-9 score documented within
	 Members with any of the following any time during the 			120-240 days (4-8 months) after the initial elevated PHQ-9 score
	member's history through the end of the measurement period:		 Depression Remission: The percentage of members who achieved remission within 120-240 days (4-8 months) after the initial elevated PHQ-9 score 	
	– Bipolar disorder – Personality disorder			 Depression Response: The percentage of members who showed response within 120-240 days (4-8 months) after the initial elevated PHQ-9 score
	 – Psychotic disorder 			the initial elevated PHQ-9 score
	 Pervasive developmental disorder 			
Adult Immunization Status (AIS-E)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. Members who die any time 	Ages 19 and older	Annual	The percentage of members who are up to date on recommended routine vaccines for influenza, tetanus and diphtheria (Td) or tetanus, diphtheria and acellular pertussis (Tdap), zoster and pneumococcal
	during the measurement year.			

Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Prenatal Immunization Status (PRS-E)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. 	N/A	Annual	The percentage of deliveries in the measurement period in which members had received influenza and tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccinations
	 Members who die any time during the measurement year. 			
	Deliveries that occurred at less than 37 weeks gestation			
Prenatal Depression Screening and Follow-up (PND-E)	Screening and Follow-upservices or elect to use a(PND-E)hospice benefit any time	N/A	Annual	The percentage of deliveries in which members were screened for clinical depression while pregnant and, if screened positive, received follow-up care:
	during the measurement year.Members who die any time during the measurement year.			 Depression screening: The percentage of deliveries in which members were screened for clinical depression during pregnancy using a standardized instrument
	Deliveries that occurred at less than 37 weeks gestation.			 Follow-up on positive screen: The percentage of deliveries in which members received follow-up care within 30 days of a positive depression screen finding
Postpartum Depression Screening and Follow-up PDS-E)	 Members who use hospice services or elect to use a hospice benefit any time 	N/A	Annual	The percentage of deliveries in which members were screened for clinical depression during the postpartum period, and if screened positive, received follow-up care:
	during the measurement yearMembers who die any time during the measurement year			 Depression screening: The percentage of deliveries in which members were screened for clinical depression using a standardized instrument during the postpartum period
				 Follow-up on positive screen: The percentage of deliveries in which members received follow-up care within 30 days of a positive depression screen finding



Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Social Need Screening and Intervention (SNS-E)	 Members who use hospice services or elect to use a hospice benefit any time during the measurement year. Members who die any time 	Any age	Annual	The percentage of members who were screened, using prespecified instruments, at least once during the measurement period for unmet food, housing, and transportation needs, and received a corresponding intervention if they screened positive:
	during the measurement year.			 Food screening: The percentage of members who were screened for food insecurity.
			1	 Food intervention: The percentage of members who received a corresponding intervention within 30 days (1 month) of screening positive for food insecurity.
				 Housing screening: The percentage of members who were screened for housing instability, homelessness, or housing inadequacy.
	FRANT	F		• Housing intervention: The percentage of members who received a corresponding intervention within 30 days (1 month) of screening positive for housing instability, homelessness, or housing inadequacy.
A BARANA	May 10 100	A Carland	W KA	 Transportation screening: The percentage of members who were screened for transportation insecurity.
				• Transportation intervention: The percentage of members who received a corresponding intervention within 30 days (1 month) of screening positive for transportation insecurity.
Medical Assistance with Smoking and Tobacco Use Cessation (MSC) —	N/A	Ages 18 and older	Annual	The following components of this measure assess different facets of providing medical assistance with smoking and tobacco use cessation:
CAHPS®				• Advising smokers and tobacco users to quit: a rolling average represents the percentage of members 18 years of age and older who were current smokers or tobacco users and who received advice to quit during the measurement year
				• Discussing cessation medications: a rolling average represents the percentage of members 18 years of age and older who were current smokers or tobacco users and who discussed or were recommended cessation medications during the measurement year
				• Discussing cessation strategies: a rolling average represents the percentage of members 18 years of age and older who were current smokers or tobacco users and who discussed or were provided cessation methods or strategies during the measurement year

Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Health Plan Survey 5.1H,	N/A	Members who have been with the plan through the year	Annual	Five composite scores summarize responses in key areas:
Adult Version (CPA) — CAHPS				1. Claims processing (commercial only)
OATH O				2. Customer service
				3. Getting care quickly
				4. Getting needed care
				5. How well doctors communicate
				Item-specific question summary rates are reported for the rating questions and each composite question. Question summary rates are also reported individually for one item summarizing the following concept:
				1. Coordination of care
Health Plan Survey 5.1H, Child Version (CPC) — CAHPS	N/A	Members who have been with the plan through the year	Annual	This measure provides information on parents' experience with their child's Medicaid organization. Results summarize member experiences through ratings, composites, and individual question summary rates.
			and the second distance of the second distanc	Four global rating questions reflect overall satisfaction:
	STATE SALA			1. Rating of All health care
				2. Rating of health plan
				3. Rating of personal doctor
				4. Rating of specialist seen most often
		ST LESS		Four composite scores summarize responses in key areas:
		X		1. Customer service
				2. Getting care quickly
				3. Getting needed care
				4. How well doctors communicate.
				Item-specific question summary rates are reported for the rating questions and each composite question. Question summary rates are also reported individually for one item summarizing the following concept:
			the second second	1. Coordination of care

Measure	Exclusions	Eligible population	Occurence	Description of measurement screening, test, or treatment needed
Children With Chronic Conditions (CCC) — CAHPS	N/A	Members who have been with the plan through the year	Annual	This measure provides information on parents' experience with their child's Medicaid organization for the population of children with chronic conditions.
				Three composites summarize satisfaction with basic components of care essential for successful treatment, management, and support of children with chronic conditions:
				1. Access to specialized services
				2. Family centered care: personal doctor who knows child
			2	3. Coordination of care for children with chronic conditions
				Item-specific question summary rates are reported for each composite question. Question summary rates are also reported individually for two items summarizing the following concepts:
				1. Access to prescription medicines
				2. Family centered care: getting needed information
Early and Periodic	N/A	Ages 0 to 20	Multiple	Screening must include:
Screening, Diagnosis and Treatment (EPSDT)			2	 Comprehensive health development history (inclusive both physical and mental health)
orogram				 Comprehensive unclothed physical exam or appropriatel draped
	all for the			 Appropriate immunizations
				Laboratory tests
16		A 76		Lead toxicity screening
· · · · · · · · · · · · · · · · · · ·		Ser and Marine		 Health education including anticipatory guidance
		311 1		Vision services
				Dental services
		PARA		Hearing services
			-	 Other necessary health care — diagnostic services and treatment to correct or ameliorate defects, physical and mental illnesses, and conditions discovered by the

Learn more about Wellpoint programs provider.wellpoint.com/nj/



Services provided by Wellpoint New Jersey, Inc. or Wellpoint Insurance Company.

NJWP-CD-040857-23